A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with Prurigo Nodularis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Subjects voluntarily sign informed consent forms prior to the commencement of any proceedings related to the study, are able to communicate smoothly with the investigator, understand and are willing to complete the study in strict compliance with the requirements of this clinical research protocol.
• The age was ≥18 at the time of signing the informed consent and gender is unlimited.
• Have prurigo Nodularis at screening.
Locations
Other Locations
China
Peking University People's Hospital
RECRUITING
Beijing
Contact Information
Primary
Huiliu Wang
huiliu.wang.hw330@hengrui.com
0518-82342973
Time Frame
Start Date: 2024-09-19
Estimated Completion Date: 2026-08-20
Participants
Target number of participants: 236
Treatments
Experimental: Treatment group A：SHR-1819 injection dose 1
Experimental: Treatment group B：SHR-1819 injection dose 2
Experimental: Treatment group C：SHR-1819 injection dose 3
Placebo_comparator: Treatment group D：placebo
Related Therapeutic Areas
Sponsors
Leads: Guangdong Hengrui Pharmaceutical Co., Ltd